NCT00920595已完成1 期
An Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP-1 and PARP-2 Inhibitor) as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors
Cephalon1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2009年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Determination of Maximum Tolerated Dose (MTD) upon Dose Limiting Toxicities (DLT) data
研究概览
简要总结
An open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 as single-agent therapy and as combination therapy with temozolomide in patients with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient has a histologically or cytologically confirmed malignant advanced solid tumor considered unresponsive or poorly responsive to accepted treatment modalities.
- •The patient has adequate hematologic assessments and adequate renal and hepatic functions as specified in the study protocol.
- •The patient has measurable or nonmeasurable disease documented with an appropriate method of evaluation according to disease characteristics.
- •The patient has had no chemotherapy for at least 3 weeks and has resolution of prior sequelae. If the patient has had prior curative radiation or prior treatment with nitrosoureas, a minimum of 4 weeks and 6 weeks, respectively, must have elapsed before treatment with CEP-
- •The patient has had no immunotherapy, including monoclonal antibody therapy, for at least 4 weeks and no hormonotherapy for at least 1 week, with the exception of patients with prostate cancer, who may continue hormonal therapy.
- •The patient has a European Cooperative Oncology Group (ECOG) performance status of 0, 1, or
- •The patient has a life expectancy of 12 weeks or more.
- •Agreement by women of childbearing potential (not surgically sterile or 2 years postmenopausal) to use a medically accepted method of contraception and continue the use of this method for the duration of the study and for 90 days after participation in the study. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
- •Agreement by men not surgically sterile or who are capable of producing offspring to practice abstinence or use a barrier method of birth control, and continue use of this method for the duration of the study and for 6 months after participation in the study.
排除标准
- •The patient has a primary brain tumor whose disease requires a systematic premedication with anticonvulsive agents.
- •The patient has baseline cardiac abnormalities outside of the specified study parameters.
- •The patient has clinically symptomatic recurrent/progressive brain metastases within 4 weeks (stable sequelae are acceptable).
- •The patient has previous hypersensitivity reactions to 1 of the components of CEP-9722, temozolomide, or dacarbazine.
- •The patient is a pregnant or breast-feeding woman. (Any women becoming pregnant during the study will be withdrawn from the study.)
- •The patient is participating in another interventional clinical study at the time of enrollment, has participated in another interventional clinical study within 4 weeks prior to enrollment, or the patient has previously been already enrolled in this study.
- •The patient has an active gastroduodenal ulcer, uncontrolled high blood pressure, uncontrolled diabetes mellitus, or uncontrolled angina pectoris; has had a recent myocardial infarction; has had a cerebrovascular event within 6 months prior to study entry; or has pre-existing coagulopathy.
- •The patient has a concomitant uncontrolled infection or severe systemic disease.
- •The patient has a known nephropathy or hepatopathy.
- •The patient is receiving concurrent treatment with an antineoplastic agent other than temozolomide.
- •The patient has had previous treatment with another PARP inhibitor.
- •The patient is unable to swallow capsules.
- •The patient has taken any medications which are contraindicated as specified in the study protocol.
- •The patient has any serious or uncontrolled nonmalignant medical disorder or psychiatric disorder.
研究组 & 干预措施
1
Experimental
CEP-9722 alone and in combination therapy with temozolomide.
干预措施: CEP-9722 (Drug)
结局指标
主要结局
Determination of Maximum Tolerated Dose (MTD) upon Dose Limiting Toxicities (DLT) data
时间窗: Up to 42 days
次要结局
- Pharmacokinetic parameters(Days 1 and 5 of Cycle 1 and on Day 5 of Cycle 2)
- Pharmacodynamics assay(Days 1, 5, and 8 of both Cycle 1 and Cycle 2)
- Efficacy - will be assessed by the proportion of patients who achieve tumor response during the study(A 14-day cycle and at least one 28-day cycle)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)Huntington's DiseaseNCT03342053Hoffmann-La Roche46
已完成
1 期
Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell LymphomaSolid Tumors or Mantle Cell LymphomaNCT01345357Cephalon24
终止
1 期
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) PatientsAcute Myeloid LeukemiaNCT01489722AstraZeneca55
已完成
3 期
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)Fabry DiseaseNCT03500094Amicus Therapeutics22
已完成
2 期
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)AcromegalyNCT03789656Crinetics Pharmaceuticals Inc.47